Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β-amyloid precursor protein

Brain Research

Volumn 953, Issue 1-2, 2002, Pages 17-30

  Apelt, Jenny ^a   Kumar, Ashok ^a   Schliebs, Reinhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Amyloid; Acetylcholinesterase; Choline acetyltransferase; Choline uptake; Muscarinic receptor; Nicotinic receptor

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINE; CHOLINE ACETYLTRANSFERASE; MUSCARINIC RECEPTOR; MUTANT PROTEIN; NICOTINIC RECEPTOR; PROTEIN PRECURSOR;

AGE; ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN TISSUE; CHOLINE UPTAKE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MEMORY DISORDER; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SWEDEN; TRANSGENIC MOUSE;

ACETYLCHOLINESTERASE; AGE FACTORS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHOLINE O-ACETYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POINT MUTATION; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SWEDEN; SYNAPTIC TRANSMISSION;

EID: 0037145719     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03262-6     Document Type: Article

References (48)

1. Andra J., Lojda Z. A histochemical method for the demonstration of acetylcholinesterase activity using semipermeable membranes. Histochemistry. 84:1986;575-579.
2. Apelt J., Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 894:2001;21-30.
3. Auld D.S., Kar S., Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 21:1998;43-49.
4. Beach T.G., Kuo Y.M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., Roher A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 59:2000;308-313.
5. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
6. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., Brunden K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging. 20:1999;581-589.
7. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:1995;749-760.
8. Blusztajn J.K., Berse B. The cholinergic neuronal phenotype in Alzheimer's disease. Metab. Brain Dis. 15:2000;45-64.
9. Bronfman F.C., Moechars D., Van Leuven F. Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein London mutant transgenic mice. Neurobiol. Dis. 7:2000;152-168.
10. Butterfield D.A. Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 10:1997;495-506.
11. Cha J.H., Farrell L.A., Ahmed S.F., Frey A., Hsiao-Ashe K.K., Young A.B., Penney J.B., Locascio J.J., Hyman B.T., Irizarry M.C. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol. Dis. 8:2001;90-102.
12. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
13. Duff K. Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis. Biochem. Soc. Symp. 67:2001;195-202.
14. Grisaru D., Sternfeld M., Eldor A., Glick D., Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264:1999;672-686.
15. Haass C., Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 75:1993;1039-1042.
16. Harkany T., O'Mahony S., Kelly J.P., Soos K., Toro I., Penke B., Luiten P.G., Nyakas C., Gulya K., Leonard B.E. Beta-amyloid (Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav. Brain Res. 90:1998;133-145.
17. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
18. Hedreen J.C., Bacon S.J., Price D.L. A modified histochemical technique to visualize acetylcholinesterase-containing axons. J. Histochem. Cytochem. 33:1985;134-140.
19. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
20. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K., McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport. 12:2001;1377-1384.
21. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33:1998;883-889.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
23. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1995;1203-1218.
24. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:1997;965-973.
25. Jaffar S., Counts S.E., Ma S.Y., Dadko E., Gordon M.N., Morgan D., Mufson E.J. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp. Neurol. 170:2001;227-243.
26. Johnson C.D., Russell R.L. A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal. Biochem. 64:1975;229-238.
27. Kar S., Seto D., Gaudreau P., Quirion R. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16:1996;1034-1040.
28. Kelly J.F., Furukawa K., Barger S.W., Rengen M.R., Mark R.J., Blanc E.M., Roth G.S., Mattson M.P. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. USA. 93:1996;6753-6758.
29. Mufson E.J., Chen E.Y., Cochran E.J., Beckett L.A., Bennett D.A., Kordower J.H. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp. Neurol. 158:1999;469-490.
30. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4:1992;303-328.
31. O'Mahony S., Harkany T., Rensink A.A., Abraham I., De Jong G.I., Varga J.L., Zarandi M., Penke B., Nyakas C., Luiten P.G., Leonard B.E. Beta-amyloid-induced cholinergic denervation correlates with enhanced nitric oxide synthase activity in rat cerebral cortex: reversal by NMDA receptor blockade. Brain Res. Bull. 45:1998;405-411.
32. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152:1998;871-877.
33. Pavia J., Alberch J., Alvarez I., Toledano A., de Ceballos M.L. Repeated intracerebroventricular administration of beta-amyloid(25-35) to rats decreases muscarinic receptors in cerebral cortex. Neurosci. Lett. 278:2000;69-72.
34. Pedersen W.A., Kloczewiak M.A., Blusztajn J.K. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA. 93:1996;8068-8071.
35. Rossner S., Schliebs R., Hartig W., Bigl V. 192IGG-saporin-induced selective lesion of cholinergic basal forebrain system: neurochemical effects on cholinergic neurotransmission in rat cerebral cortex and hippocampus. Brain Res. Bull. 38:1995;371-381.
36. Sberna G., Saez-Valero J., Li Q.X., Czech C., Beyreuther K., Masters C.L., McLean C.A., Small D.H. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J. Neurochem. 71:1998;723-731.
37. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 258:1992;126-129.
38. Sidman R.L., Angevine J.B., Pierce E.T. Atlas of the Mouse Brain and Spinal Cord. 1971;Harvard University Press, Cambridge.
39. Sihver W., Gunther P., Schliebs R., Bigl V. Repeated administration of tacrine to normal rats: effects on cholinergic, glutamatergic, and GABAergic receptor subtypes in rat brain using receptor autoradiography. Neurochem. Int. 31:1997;693-703.
40. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:1998;2212-2215.
41. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24:2001;1217-1281.
42. Strosznajder J.B., Zambrzycka A., Kacprzak M.D., Strosznajder R.P. Amyloid beta peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. J. Mol. Neurosci. 12:1999;101-109.
43. Sturchler-Pierrat C., Staufenbiel M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann. N.Y. Acad. Sci. 920:2000;134-139.
44. Tomidokoro Y., Harigaya Y., Matsubara E., Ikeda M., Kawarabayashi T., Okamoto K., Shoji M. Impaired neurotransmitter systems by Abeta amyloidosis in APPsw transgenic mice overexpressing amyloid beta protein precursor. Neurosci. Lett. 292:2000;155-158.
45. Walch C., Schliebs R., Bigl V. Effect of early visual pattern deprivation on development and laminar distribution of cholinergic markers in rat visual cortex. Experientia, Suppl. 57:1989;295-304.
46. Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble A beta. Neurobiol. Aging. 15:1994;143-152.
47. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 19:1999;2706-2716.
48. Yatin S.M., Aksenov M., Butterfield D.A. The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem. Res. 24:1999;427-435.